WO2013109212A1 - Formulations en poudre sèche comprenant de la ciclésonide - Google Patents

Formulations en poudre sèche comprenant de la ciclésonide Download PDF

Info

Publication number
WO2013109212A1
WO2013109212A1 PCT/TR2013/000024 TR2013000024W WO2013109212A1 WO 2013109212 A1 WO2013109212 A1 WO 2013109212A1 TR 2013000024 W TR2013000024 W TR 2013000024W WO 2013109212 A1 WO2013109212 A1 WO 2013109212A1
Authority
WO
WIPO (PCT)
Prior art keywords
range
pharmaceutical formulation
formulation according
excipient
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2013/000024
Other languages
English (en)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2013109212A1 publication Critical patent/WO2013109212A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Definitions

  • Corticosteroids used in the treatment of respiratory tract diseases such as asthma and COPD are synthetic and potent anti-inflammatory drugs similar to natural corticosteroid hormones secreted by adrenal glands. It is known that corticosteroids are quite effective drugs in asthma treatment. Ciclesonide is a molecule which belongs to said group.
  • the average particle size ratio of the fine grained excipient to the coarse grained excipient is in the range of 1 :30 to 1 :2, preferably in the range of 1 :20 to 1 :5, more preferably in the range of 1 : 15 to 1 :10.
  • the amount of ciclesonide in said formulation is in the range of 100 to 750 ⁇ g, preferably in the range of 150 to 550 ⁇ g,
  • the inventors have seen that characteristics such as proper flow, particularly homogenous particle dispersion and dose uniformity of the formulation are ensured and therefore the sufficient amount of the active agent reaches to the lungs more easily in the case that the ratio of fine grained excipient to coarse grained excipient constituting the excipient combination is in the range of 1 :1 to 1 :25 by weight, preferably in the range of 1 :1 to 1 : 10 by weight, more preferably in the range of 1 : 1.5 to 1 :5 by weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/TR2013/000024 2012-01-16 2013-01-16 Formulations en poudre sèche comprenant de la ciclésonide Ceased WO2013109212A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201200491 2012-01-16
TR2012/00491 2012-01-16

Publications (1)

Publication Number Publication Date
WO2013109212A1 true WO2013109212A1 (fr) 2013-07-25

Family

ID=48237228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000024 Ceased WO2013109212A1 (fr) 2012-01-16 2013-01-16 Formulations en poudre sèche comprenant de la ciclésonide

Country Status (1)

Country Link
WO (1) WO2013109212A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482934A (en) 1990-09-07 1996-01-09 Especialidades Latinas Medicamentos Universales, S.A. (Elmu, S.A.) Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
WO2004105727A2 (fr) * 2003-05-28 2004-12-09 Aventis Pharma Limited Produit pharmaceutique stabilise
WO2008102128A2 (fr) * 2007-02-19 2008-08-28 Cipla Limited Combinaisons pharmaceutiques
WO2011093814A2 (fr) * 2010-01-29 2011-08-04 Mahmut Bilgic Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide
WO2011093819A2 (fr) * 2010-01-28 2011-08-04 Mahmut Bilgic Nouvelle composition pharmaceutique combinée comprenant du tiotropium

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482934A (en) 1990-09-07 1996-01-09 Especialidades Latinas Medicamentos Universales, S.A. (Elmu, S.A.) Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
WO2004105727A2 (fr) * 2003-05-28 2004-12-09 Aventis Pharma Limited Produit pharmaceutique stabilise
WO2008102128A2 (fr) * 2007-02-19 2008-08-28 Cipla Limited Combinaisons pharmaceutiques
WO2011093819A2 (fr) * 2010-01-28 2011-08-04 Mahmut Bilgic Nouvelle composition pharmaceutique combinée comprenant du tiotropium
WO2011093814A2 (fr) * 2010-01-29 2011-08-04 Mahmut Bilgic Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide

Similar Documents

Publication Publication Date Title
EP2528585B1 (fr) Compositions pharmaceutiques comprenant du tiotropium, du formotérol et du budésonide
EP2528596B1 (fr) Composition sous forme de poudre sèche pour administration par inhalation comprenant une combinaison de bromure de tiotropium, de xynafoate de salmeterol et de propionate de fluticasone.
EP2533777B1 (fr) Compositions pharmaceutiques contenant de la fluticasone, du tiotropium et du cromoglycate de sodium
EP2528600B1 (fr) Composition pharmaceutique de poudre sèche comprenant le tiotropium et le fluticasone
WO2011093819A2 (fr) Nouvelle composition pharmaceutique combinée comprenant du tiotropium
WO2011093820A2 (fr) Composition pharmaceutique combinée comprenant du tiotropium
WO2013109210A1 (fr) Formulations en poudre sèche comprenant du budésonide
EP2480203B1 (fr) Formulation de poudre sèche de tiotropium contenue dans une bande alvéolée thermoformée
EP2804590A1 (fr) Formulations en poudre sèche comprenant du tiotropium et du carmotérol
WO2013109220A1 (fr) Formulations en poudre sèche comprenant du tiotropium, du formotérol et du budésonide
WO2013009271A1 (fr) Nouvelle formulation améliorée de poudre sèche
EP2804584A1 (fr) Formulations en poudre sèche comprenant du carmotérol et de la ciclésonide
EP2804589A1 (fr) Formulations pharmaceutiques comprenant de l'aztréonam
WO2013109212A1 (fr) Formulations en poudre sèche comprenant de la ciclésonide
EP2528597B1 (fr) Composition sous form de poudre sèche comprenant une combinaison de bromure de tiotropium, fumarate de formoterol et de furoate de mometasone
WO2011093811A2 (fr) Préparations pharmaceutiques comprenant du formotérol et du fluticasone
WO2013109209A1 (fr) Formulations en poudre sèche comprenant de la fluticasone
EP2515888B1 (fr) Poudre sèche pour inhalation comprenant tiotropium
WO2013109207A1 (fr) Formulations de poudre sèche comprenant de la mométasone
WO2013109213A2 (fr) Formulations pharmaceutiques comprenant du tiotropium
WO2013109208A1 (fr) Formulations comprenant du formotérol utilisé comme agent actif
EP2804583A1 (fr) Formulations en poudre sèche comprenant du r-formotérol utilisé comme agent actif
EP2480202A2 (fr) Bande alvéolée thermoformée contenant une combinaison qui renferme du tiotropium
US8834931B2 (en) Dry powder formulation containing tiotropium for inhalation
WO2011093812A2 (fr) Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13720136

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13720136

Country of ref document: EP

Kind code of ref document: A1